Preclinical evidence of Yinchenhao decoction on cholestasis: A systematic review and meta‐analysis of animal studies. (25th September 2020)

• Record Type: Journal Article
• Authors: Shi, Kaiyun; Wen, Jianxia; Zeng, Jinhao; Guo, Yaoguang; Hu, Jike; Li, Cong; Zhao, Yanling; Ma, Xiao
• Is Part Of: Phytotherapy research. Volume 35:Number 1(2021)
• Page Start: 138
• Page End: 154
• Publication Date: 2020-09-25
• Subjects: cholestasis -- meta‐analysis -- traditional Chinese medicine -- Yinchenhao decoction; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.6806
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract : Cholestasis is an important cause of liver fibrosis and cirrhosis. Yinchenhao decoction has been used as a well‐known traditional Chinese medicine used in the treatment of cholestasis for over 2, 000 years. The purpose of this systematic review is to evaluate the preclinical evidence of Yinchenhao decoction on cholestasis models. The following databases were searched from inception to February 2020. Chinese National Knowledge Infrastructure, VIP medicine information system, Wanfang Database, PubMed, Web of Science, Embase and the Cochrane Library were searched. The content concerned Yinchenhao decoction on different animal model experiments for the treatment of cholestasis. The methodological quality of the included studies was assessed based on the SYstematic Review Center for Laboratory animal Experimentation Animal Experiment Bias Risk Assessment Tool. A meta‐analysis was conducted with RevMan 5.3 software according to the Cochrane tool. Nineteen studies on a total of 404 animals were included with five kinds of experimental animal models. The results showed that serum total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin and total bile acid in the group treated with Yinchenhao decoction were significantly lower than those in the model group ( P < 0.00001). The alanine aminotransferase (ALT), aspartate aminotransferase and alkaline phosphatase levels in the Yinchenhao decoction group were also significantly reduced ( P < 0.00001). The subgroup analysis of the different models showed that Yinchenhao decoction had a significant effect on the bile duct ligation model, and there was a significant reduction in TBIL, DBIL and ALT levels ( P < 0.00001) in ANIT‐induced cholestasis. After 24 hours of Yinchenhao decoction treatment, there was no significant difference in TBIL levels ( P = 0.34), but after 48 and 72 hours of treatment, the TBIL levels were significantly reduced compared with the model group ( P < 0.00001). There was no significant difference in DBIL after 48 hours of administration ( P = 0.26), but compared with the model group, Yinchenhao decoction could significantly reduce the DBIL levels after 48 hours of treatment ( P < 0.0003). Yinchenhao decoction could significantly reduce the ALT levels after 24, 48 and 72 hours ( P < 0.006). Yinchenhao decoction was able to significantly reduce the levels of TBIL, DBIL and ALT on different rat species: Wistar and Sprague Dawley ( P = 0.0001; P = 0.0002). The preclinical evidence indicated that Yinchenhao decoction might be a potent and promising agent for cholestasis. Moreover, this conclusion should be further confirmed with more well‐designed researches. Abstract : Workflow of present study.